AstraZeneca Statistics
Total Valuation
AstraZeneca has a market cap or net worth of $285.54 billion. The enterprise value is $312.79 billion.
Important Dates
The last earnings date was Wednesday, April 29, 2026, before market open.
| Earnings Date | Apr 29, 2026 |
| Ex-Dividend Date | Feb 20, 2026 |
Share Statistics
AstraZeneca has 1.55 billion shares outstanding. The number of shares has decreased by -0.08% in one year.
| Current Share Class | 1.55B |
| Shares Outstanding | 1.55B |
| Shares Change (YoY) | -0.08% |
| Shares Change (QoQ) | -0.13% |
| Owned by Insiders (%) | 0.04% |
| Owned by Institutions (%) | 67.42% |
| Float | 1.54B |
Valuation Ratios
The trailing PE ratio is 27.48 and the forward PE ratio is 17.31.
| PE Ratio | 27.48 |
| Forward PE | 17.31 |
| PS Ratio | 4.72 |
| Forward PS | 4.36 |
| PB Ratio | 6.03 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 25.28 |
| P/OCF Ratio | 20.08 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 15.64, with an EV/FCF ratio of 27.70.
| EV / Earnings | 30.11 |
| EV / Sales | 5.18 |
| EV / EBITDA | 15.64 |
| EV / EBIT | 20.96 |
| EV / FCF | 27.70 |
Financial Position
The company has a current ratio of 0.91, with a Debt / Equity ratio of 0.72.
| Current Ratio | 0.91 |
| Quick Ratio | 0.70 |
| Debt / Equity | 0.72 |
| Debt / EBITDA | 1.67 |
| Debt / FCF | 3.01 |
| Interest Coverage | 10.59 |
Financial Efficiency
Return on equity (ROE) is 23.48% and return on invested capital (ROIC) is 16.40%.
| Return on Equity (ROE) | 23.48% |
| Return on Assets (ROA) | 8.47% |
| Return on Invested Capital (ROIC) | 16.40% |
| Return on Capital Employed (ROCE) | 18.32% |
| Weighted Average Cost of Capital (WACC) | 5.50% |
| Revenue Per Employee | $635,531 |
| Profits Per Employee | $109,243 |
| Employee Count | 95,100 |
| Asset Turnover | 0.55 |
| Inventory Turnover | 1.80 |
Taxes
In the past 12 months, AstraZeneca has paid $2.52 billion in taxes.
| Income Tax | 2.52B |
| Effective Tax Rate | 19.52% |
Stock Price Statistics
The stock price has increased by +23.40% in the last 52 weeks. The beta is 0.28, so AstraZeneca's price volatility has been lower than the market average.
| Beta (5Y) | 0.28 |
| 52-Week Price Change | +23.40% |
| 50-Day Moving Average | 195.14 |
| 200-Day Moving Average | 175.58 |
| Relative Strength Index (RSI) | 31.44 |
| Average Volume (20 Days) | 1,936,808 |
Short Selling Information
The latest short interest is 1.74 million, so 0.11% of the outstanding shares have been sold short.
| Short Interest | 1.74M |
| Short Previous Month | 1.98M |
| Short % of Shares Out | 0.11% |
| Short % of Float | 0.11% |
| Short Ratio (days to cover) | 0.92 |
Income Statement
In the last 12 months, AstraZeneca had revenue of $60.44 billion and earned $10.39 billion in profits. Earnings per share was $6.64.
| Revenue | 60.44B |
| Gross Profit | 49.26B |
| Operating Income | 14.92B |
| Pretax Income | 12.91B |
| Net Income | 10.39B |
| EBITDA | 19.99B |
| EBIT | 14.92B |
| Earnings Per Share (EPS) | $6.64 |
Full Income StatementBalance Sheet
The company has $7.68 billion in cash and $34.03 billion in debt, with a net cash position of -$26.35 billion or -$17.01 per share.
| Cash & Cash Equivalents | 7.68B |
| Total Debt | 34.03B |
| Net Cash | -26.35B |
| Net Cash Per Share | -$17.01 |
| Equity (Book Value) | 47.38B |
| Book Value Per Share | 30.56 |
| Working Capital | -2.96B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $14.22 billion and capital expenditures -$2.93 billion, giving a free cash flow of $11.29 billion.
| Operating Cash Flow | 14.22B |
| Capital Expenditures | -2.93B |
| Depreciation & Amortization | 5.07B |
| Net Borrowing | 1.19B |
| Free Cash Flow | 11.29B |
| FCF Per Share | $7.29 |
Full Cash Flow StatementMargins
Gross margin is 81.51%, with operating and profit margins of 24.69% and 17.19%.
| Gross Margin | 81.51% |
| Operating Margin | 24.69% |
| Pretax Margin | 21.37% |
| Profit Margin | 17.19% |
| EBITDA Margin | 33.08% |
| EBIT Margin | 24.69% |
| FCF Margin | 18.68% |
Dividends & Yields
This stock pays an annual dividend of $3.20, which amounts to a dividend yield of 1.77%.
| Dividend Per Share | $3.20 |
| Dividend Yield | 1.77% |
| Dividend Growth (YoY) | 3.23% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 48.19% |
| Buyback Yield | 0.08% |
| Shareholder Yield | 1.85% |
| Earnings Yield | 3.64% |
| FCF Yield | 3.95% |
Dividend DetailsAnalyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | 5.51% |
| EPS Growth Forecast (5Y) | 4.06% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside | |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
AstraZeneca has an Altman Z-Score of 3.35 and a Piotroski F-Score of 7.
| Altman Z-Score | 3.35 |
| Piotroski F-Score | 7 |
